TYK Medicines, Inc (HKG:2410)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
32.55
-2.55 (-7.26%)
Apr 3, 2025, 4:08 PM HKT
124.79%
Market Cap 13.02B
Revenue (ttm) 113.87K
Net Income (ttm) -411.79M
Shares Out 370.84M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,467,500
Average Volume 2,325,625
Open 35.10
Previous Close 35.10
Day's Range 30.20 - 35.30
52-Week Range 12.86 - 56.55
Beta n/a
RSI 51.79
Earnings Date Mar 27, 2025

About TYK Medicines

TYK Medicines, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of therapies to address unmet medical needs in cancer treatment. Its lead product candidate is TY-9591, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor for the treatment of brain metastases from non-small cell lung cancer (NSCLC) with EGFR mutations, and in locally advanced or metastatic NSCLC with EGFR L858R mutation. The company also develops TY-302, an oral cyclin-depe... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Country China
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2410
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.